A Phase 1/2a, Multi-Center, Dose Escalation/Dose Expansion, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2019
Price : $35 *
At a glance
- Drugs JAB-3068 (Primary)
- Indications Head and neck cancer; Lymphoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Jacobio Pharmaceuticals
- 18 Dec 2018 Status changed from not yet recruiting to recruiting.
- 20 Sep 2018 Planned initiation date changed from 1 Jul 2018 to 1 Oct 2018.
- 27 Jun 2018 New trial record